Health
Moderna Receives FDA Fast Track Designation for Respiratory Syncytial Virus (RSV) Vaccine (mRNA-1345) – Business Wire
Moderna receives FDA Fast Track designation for Respiratory Syncytial Virus (RSV) vaccine (mRNA-1345).
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for mRNA-1345,…
Continue Reading
-
Noosa News22 hours agoQueensland government to review greenhouse gas emission reduction targets
-
Noosa News23 hours agoYoung voices shape Sunshine Coast’s future
-
Business22 hours ago2 Low Cost Active ASX ETFs to consider
-
Noosa News20 hours agoStar Entertainment signs $300m lifeline deal with US gaming giant Bally’s